NYSE · Healthcare · Medical Instruments & Supplies · Canada
Bausch + Lomb Corp is a mid cap company (market value between $2 billion and $10 billion) in the Medical Instruments & Supplies industry.
Bausch + Lomb is an integrated eye health company offering contact lenses, intraocular lenses, surgical devices, prescription medications, vitamin supplements, and lens care products across three segments: Vision Care, Pharmaceuticals, and Surgical. The company serves patients and consumers globally through ophthalmologists, retailers, and direct channels.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Bausch + Lomb Corp stock.
Overvalued: intrinsic value $11.70 per share, market price $20.00, margin of safety -70.9% (as of 2026-10-30).
Discounting its cash flows at 6.6% values the shares at $11.70; the price of $20.00 is 71% above that value, and 85% of that value comes from beyond year five.
1 more funds hold it; the full list is part of the paid plan.
All 51 Medical Instruments & Supplies stocks
11 more in this industry show a wider margin of safety.
BLCO is overvalued (as of the 2026-10-30 close). Discounting its cash flows at 6.6% values the shares at $11.70; the price of $20.00 is 71% above that value, and 85% of that value comes from beyond year five.
$11.70 per share (as of the 2026-10-30 close), against a market price of $20.00. That is a margin of safety of -70.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.